← Eichor
Condition: Ureteric Injury Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ureteric Injury

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
Phase 4 · 1 location(s) · Prove pharm · NCT06054880
Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones
NA · 1 location(s) · Ningbo No. 1 Hospital · NCT06987760
Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure
NA · 1 location(s) · Ain Shams University · NCT06830577
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
NA · 2 location(s) · Rabin Medical Center · NCT05992363
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
Phase 4 · 1 location(s) · Prove pharm · NCT06085183
Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery
Phase 2/Phase 3 · 10 location(s) · Curadel Surgical Innovations, Inc. · NCT06101745
Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
Phase 1 · 1 location(s) · MediBeacon · NCT07080008
A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
Phase 2 · 1 location(s) · Alume Biosciences, Inc. · NCT06662097
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.